Arbutus Biopharma Corp (ABUS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | 10,739 | 1,764 | 1,339 | 1,726 |
| Restructuring costs | 165 | 12,373 | 3,625 | - |
| Research and development | 5,498 | 8,959 | 14,273 | 15,551 |
| General and administrative | 3,328 | 5,832 | 4,537 | 7,547 |
| Change in fair value of contingent consideration | 260 | 299 | 344 | 211 |
| Total operating expenses | 9,251 | 27,463 | 22,779 | 23,309 |
| Gain (loss) from operations | 1,488 | -25,699 | -21,440 | -21,583 |
| Interest expense | - | - | - | 34 |
| Interest income | 1,042 | 1,197 | 1,747 | 1,829 |
| Interest expense | 28 | 28 | 29 | - |
| Foreign exchange gain (loss) | 21 | 4 | 5 | -8 |
| Total other income | 1,035 | 1,173 | 1,723 | 1,787 |
| Net income (loss) | 2,523 | -24,526 | -19,717 | -19,796 |
| Unrealized (loss) gain on available-for-sale securities | -21 | -31 | 218 | 63 |
| Comprehensive income (loss) | 2,502 | -24,557 | -19,499 | -19,733 |
| Basic (in shares) | 191,551,282 | 190,707,085 | 188,997,194 | 188,041,489 |
| Basic (in usd per share) | 0.01 | -0.13 | -0.1 | -0.11 |
| Diluted (in shares) | 192,399,733 | 190,707,085 | 188,997,194 | 188,041,489 |
| Diluted (in usd per share) | 0.01 | -0.13 | -0.1 | -0.11 |